Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.
Simple Summary: There have been many advances in therapeutic options for relapsed/refractory follicular lymphoma (R/R FL) in Canada and internationally. Herein, we provide a summary of the landmark studies leading to approval of different therapies and consensus recommendations for the management of...
| Publicado en: | Current Oncology Vol. 33; no. 8; pp. 451 - 474 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196621278&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196621278 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Aug2026 vid: 33 iid: 8 pid: 97109 pub: MDPI artinfo: ui: 196621278 10.3390/curroncol33080451 196621278 ppf: 451 ppct: 23 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma. aug: au: Owen, Carolyn Lemieux, Christopher Bosch, Mark Davison, Kelly Forward, Nicholas Kanasara, Roopesh Keating, Mary Margaret Prica, Anca Stewart, Colin Vijenthira, Abi Sehn, Laurie H. affil: Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, AB T2N 1N4, Canada sug: ab: Simple Summary: There have been many advances in therapeutic options for relapsed/refractory follicular lymphoma (R/R FL) in Canada and internationally. Herein, we provide a summary of the landmark studies leading to approval of different therapies and consensus recommendations for the management of R/R FL in Canada. Relapsed and/or refractory follicular lymphoma (R/R FL) remains a therapeutic challenge due to its chronic relapsing course and increasingly complex treatment landscape. Novel therapies, including immunomodulatory combinations, bispecific antibodies (BsAbs), Bruton tyrosine kinase inhibitors, and chimeric antigen receptor (CAR) T-cell therapies, have expanded treatment options and increased the complexity of treatment selection and sequencing. The Canadian Hematology Consensus Group (CHCG) convened a national panel of lymphoma experts to develop evidence-informed consensus recommendations for the management of adults with R/R FL in the Canadian context. Clinical questions informed a structured literature review of studies published through February 2026, including randomized trials, phase II studies, observational data, conference proceedings, and relevant guidelines. Recommendations were developed using a modified Delphi consensus process and graded using a framework adapted from the British Committee for Standards in Haematology. Key recommendations include repeat biopsy to exclude histologic transformation at relapse, individualized treatment selection based on timing of relapse and patient-specific factors, preferential use of lenalidomide-rituximab (LenR)-based triplet combinations in most second-line settings, and incorporation of BsAb and CAR T-cell therapy in third-line and later disease. These recommendations aim to provide practical guidance for Canadian clinicians managing patients with R/R FL. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|